

Aparna R Parikh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4907047/publications.pdf>

Version: 2024-02-01

70
papers

3,705
citations

361296

20
h-index

149623

56
g-index

74
all docs

74
docs citations

74
times ranked

5485
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 242-252.	0.7	4
2	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, e502-e509.	2.1	6
3	Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with <i>KRAS</i> Wild-type Metastatic Colorectal Cancer: A Meta-analysis. <i>Oncologist</i> , 2022, 27, 371-379.	1.9	8
4	Methylated Septin9 (<i>mSEPT9</i>): A Promising Blood-Based Biomarker for the Detection and Screening of Early-Onset Colorectal Cancer. <i>Cancer Research Communications</i> , 2022, 2, 90-98.	0.7	8
5	EPR22-117: Evaluation of the Influence of the BRAF V600E Mutation and of the Microsatellite Instability on the Overall Survival (OS) of Metastatic CRC Patients Based on Real World Data. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, EPR22-117.	2.3	0
6	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. <i>Cancer Discovery</i> , 2022, 12, 1462-1481.	7.7	30
7	Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, , .	0.9	0
8	Correlation of clinical, pathologic, and genetic parameters with intratumoral immune milieu in mucinous adenocarcinoma of the colon. <i>Modern Pathology</i> , 2022, 35, 1723-1731.	2.9	7
9	fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing. <i>Bioinformatics Advances</i> , 2022, 2, .	0.9	4
10	Abstract CT134: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs). <i>Cancer Research</i> , 2022, 82, CT134-CT134.	0.4	1
11	Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. <i>Journal of Clinical Oncology</i> , 2022, 40, 2846-2857.	0.8	77
12	Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e1587-e1593.	1.4	6
13	Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. <i>Cancer</i> , 2021, 127, 619-627.	2.0	7
14	Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2859-2870.	0.9	8
15	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132.	1.5	30
16	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	2.3	758
17	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5586-5594.	3.2	178
18	Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience. <i>Oncologist</i> , 2021, 26, e1581-e1588.	1.9	10

#	ARTICLE	IF	CITATIONS
19	Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1846-e1855.	1.4	9
20	The Use of Single-Agent Versus Multiple-Agent Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Rectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	0.6	0
21	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 6343-6353.	3.2	8
22	Abstract CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF. , 2021, , .		1
23	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021, 21, 1119-1126.	0.5	13
24	Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials. <i>Current Treatment Options in Oncology</i> , 2021, 22, 100.	1.3	11
25	ASO Visual Abstract: Neoadjuvant versus Postoperative Chemoradiotherapy Is Associated with Improved Survival in Patients with Resectable Gastric and Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 690-691.	0.7	0
26	Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2856-2865.	0.7	3
27	Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021, , .	2.9	1
28	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. <i>Nature Cancer</i> , 2021, 2, 1124-1135.	5.7	112
29	Gender, Productivity, and Philanthropic Fundraising in Academic Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1401-1406.	2.3	2
30	The Unintentional Perpetuation of the Gender Divide. <i>Journal of General Internal Medicine</i> , 2020, 35, 910-912.	1.3	0
31	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. <i>Oncologist</i> , 2020, 25, e398-e404.	1.9	10
32	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1246-1262.	1.5	16
33	ASCO Voices 2020. <i>Journal of Clinical Oncology</i> , 2020, 38, 3231-3232.	0.8	0
34	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020, 25, 997-1000.	1.9	6
35	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	0.7	4
36	Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2020, 25, 1015-1022.	1.9	11

#	ARTICLE	IF	CITATIONS
37	The Program for Enhanced Training in Cancer: An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. <i>JCO Global Oncology</i> , 2020, 6, 13-13.	0.8	1
38	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 9778.	1.6	5
39	First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE ₂ -receptor E-type 4 (EP4), in patients with advanced cancers. , 2020, 8, e000222.		34
40	Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4814-4822.	3.2	82
41	Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 230, 912-924.	0.2	42
42	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	3.2	67
43	NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 806-815.	2.3	310
44	Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 90-95.	0.4	20
45	Concurrent therapy with immune checkpoint inhibitors and TNF α blockade in patients with gastrointestinal immune-related adverse events. , 2019, 7, 226.		89
46	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	15.2	359
47	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>JAMA Oncology</i> , 2019, 5, 1020.	3.4	353
48	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , 2019, 24, e275-e283.	1.9	18
49	POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. <i>Oncologist</i> , 2019, 24, 1557-1561.	1.9	12
50	Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , 2019, 24, 193-201.	1.9	16
51	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.	1.9	73
52	Response to Anti-EGFR Therapy in Patients with BRAF non-V600 μ Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7089-7097.	3.2	79
53	MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2988-2995.	3.2	42
54	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. <i>Annals of Surgery</i> , 2019, 269, 733-740.	2.1	235

#	ARTICLE	IF	CITATIONS
55	A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, 391-391.	0.8	8
56	Outcomes following liver SBRT for metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 418-418.	0.8	2
57	Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with BRAF non-V600 mutated metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 659-659.	0.8	2
58	Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1109-1133.	2.3	92
59	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer. Cancer Discovery, 2018, 8, 417-427.	7.7	61
60	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery, 2018, 8, 164-173.	7.7	243
61	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Annals of Surgical Oncology, 2018, 25, 4027-4034.	0.7	21
62	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942.	1.3	21
63	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Practical Radiation Oncology, 2018, 8, 414-421.	1.1	17
64	Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.. Journal of Clinical Oncology, 2018, 36, 49-49.	0.8	3
65	HER2 positivity in brain metastases from gastrointestinal primary malignancies.. Journal of Clinical Oncology, 2018, 36, 61-61.	0.8	1
66	The immune milieu of anal squamous cell carcinoma and implications of IDO expression on outcome.. Journal of Clinical Oncology, 2018, 36, 659-659.	0.8	1
67	Fast-TRKing Drug Development for Rare Molecular Targets. Cancer Discovery, 2017, 7, 934-936.	7.7	9
68	Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2017, 21, 1831-1840.	0.9	14
69	Medical Oncologists'™ Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. Journal of Oncology Practice, 2017, 13, e185-e196.	2.5	17
70	ReCAP: Oncologists'™ Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer. Journal of Oncology Practice, 2016, 12, 259-260.	2.5	3